Study identifier:D5162C00048
ClinicalTrials.gov identifier:NCT05526755
EudraCT identifier:2021-003024-33
CTIS identifier:N/A
An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in participants with EGFRm-positive Stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy
Stage II-IIIB Non-small Cell Lung Carcinoma
Phase 2
No
Osimertinib 80 mg/40 mg
All
196
Interventional
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Osimertinib Participants will receive osimertinib (AZD9291). | - |